{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:59:50Z","timestamp":1781020790189,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["CA230972"],"award-info":[{"award-number":["CA230972"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["BC240179"],"award-info":[{"award-number":["BC240179"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102117","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:48:41Z","timestamp":1771400921000},"page":"102117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-4824","authenticated-orcid":false,"given":"Paige O.","family":"Mirsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-099X","authenticated-orcid":false,"given":"John","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-3330","authenticated-orcid":false,"given":"Albert D.","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102117_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.omtm.2017.11.001","article-title":"Improved expansion and in vivo function of patient T cells by a serum-free medium","volume":"8","author":"Medvec","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102117_bib0002","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/cpr.12063","article-title":"Serum-free media for the production of human mesenchymal stromal cells: a review","volume":"46","author":"Gottipamula","year":"2013","journal-title":"Cell Prolif"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102117_bib0003","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3892\/ijmm.2023.5261","article-title":"Impact of serum\u2011free media on the expansion and functionality of CD19.CAR T\u2011cells","volume":"52","author":"Eberhardt","year":"2023","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jcyt.2026.102117_bib0004","first-page":"462","article-title":"Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes","volume":"20","author":"Nowell","year":"1960","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102117_bib0005","series-title":"Experimental immunochemistry. 2d, rev. and enl","author":"Kabat","year":"1961"},{"key":"10.1016\/j.jcyt.2026.102117_bib0006","series-title":"Handbook of experimental immunology. 2","article-title":"Lymphocyte Response to Activators","author":"Waithe","year":"1978"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102117_bib0007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcyt.2016.11.011","article-title":"A consensus introduction to serum replacements and serum-free media for cellular therapies","volume":"19","author":"Karnieli","year":"2017","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102117_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-based product characterization for clinical trials: an FDA perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102117_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2025.1612903","article-title":"Fetal bovine serum: how to leave it behind in the pursuit of more reliable science","volume":"7","author":"Weber","year":"2025","journal-title":"Front Toxicol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102117_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000356236","article-title":"Human-derived alternatives to fetal bovine serum in cell culture","volume":"40","author":"Witzeneder","year":"2013","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102117_bib0011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jcp.21081","article-title":"Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine","volume":"213","author":"Lange","year":"2007","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102117_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yexcr.2018.02.017","article-title":"Human serum alters cell culture behavior and improves spheroid formation in comparison to fetal bovine serum","volume":"365","author":"Heger","year":"2018","journal-title":"Exp Cell Res"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102117_bib0013","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jcyt.2025.06.011","article-title":"Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration","volume":"27","author":"Donnenberg","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102117_bib0014","unstructured":"AABB_Global_Standards_Committee. Fundamental Standards for Blood Banks and Transfusion Services 2018:[92 p.]."},{"issue":"1","key":"10.1016\/j.jcyt.2026.102117_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10529-017-2437-8","article-title":"Examining the sources of variability in cell culture media used for biopharmaceutical production","volume":"40","author":"McGillicuddy","year":"2018","journal-title":"Biotechnol Lett"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:29Z","timestamp":1781018369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926000794"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102117","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-house manufacture of plasma-derived human AB serum for use in cellular therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102117"}}